(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.63%.
Quince Therapeutics's earnings in 2026 is -$92,476,000.On average, 5 Wall Street analysts forecast QNCX's earnings for 2026 to be -$154,974,364, with the lowest QNCX earnings forecast at -$304,199,475, and the highest QNCX earnings forecast at -$1,025,200. On average, 5 Wall Street analysts forecast QNCX's earnings for 2027 to be -$146,398,489, with the lowest QNCX earnings forecast at -$326,326,698, and the highest QNCX earnings forecast at -$4,228,948.
In 2028, QNCX is forecast to generate $4,851,594 in earnings, with the lowest earnings forecast at -$3,986,887 and the highest earnings forecast at $23,494,155.